Abstract P3-04-07: The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy
Agostina Nardone(AstraZeneca (Spain)), Rachel Schiff(Baylor College of Medicine), C. Kent Osborne(Texas Oncology), Claudia De Angelis(University of Naples Federico II), Meghana V. Trivedi(University of Houston), Hazel M. Weir(AstraZeneca (United Kingdom)), MJ Shea(AstraZeneca (United Kingdom)), G C Chamness(AstraZeneca (United Kingdom)), Xin Fu(AstraZeneca (United Kingdom)), Tamika Mitchell(Baylor College of Medicine), ML Cataldo(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
|Cancer Research|2008|494